Novartis has shown that the absence of pyruvate kinase M2 isozyme has no effect on cancer cell proliferation in mice, thus suggesting PKM2 inhibition alone might not be an effective strategy to stop tumor growth. Biotechs working on PKM2 modulators think it is too early to write off the target.